FilingReader Intelligence
Huadong Medicine's subsidiary gets clinical trial nod
June 12, 2025 at 12:35 AM UTC•By FilingReader AI
Huadong Medicine (SZSE:000963) announced today that its wholly-owned subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd. ("Sino-American Huadong"), has received approval from the National Medical Products Administration (NMPA) to conduct Phase III clinical trials for its 0.3% roflumilast foam (ZORYVE®). The trial will evaluate the efficacy and safety of the drug in patients with seborrheic dermatitis.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime